Cresco Labs Toekomstige groei

Future criteriumcontroles 1/6

De verwachting is dat Cresco Labs de winst en omzet met respectievelijk 137.8% en 7.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 104.2% per jaar.

Belangrijke informatie

137.8%

Groei van de winst

104.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	54.4%
Inkomstengroei	7.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04

Winst- en omzetgroeiprognoses

CNSX:CL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	853	N/A	N/A	N/A	1
12/31/2025	777	-1	60	104	8
12/31/2024	743	-56	64	109	8
6/30/2024	735	-172	59	91	N/A
3/31/2024	747	-155	48	92	N/A
12/31/2023	756	-176	1	59	N/A
9/30/2023	767	-339	-1	65	N/A
6/30/2023	786	-234	-23	50	N/A
3/31/2023	806	-211	-44	25	N/A
12/31/2022	825	-212	-67	19	N/A
9/30/2022	842	-65	-38	53	N/A
6/30/2022	848	-326	-62	34	N/A
3/31/2022	841	-318	-114	-2	N/A
12/31/2021	806	-320	-83	14	N/A
9/30/2021	750	-360	-99	-3	N/A
6/30/2021	687	-73	-74	20	N/A
3/31/2021	573	-105	-25	43	N/A
12/31/2020	463	-102	-97	-8	N/A
9/30/2020	345	-76	-149	-34	N/A
6/30/2020	231	-98	-186	-70	N/A
3/31/2020	168	-64	-185	-57	N/A
12/31/2019	124	-43	-121	-25	N/A
9/30/2019	101	-20	-94	-29	N/A
6/30/2019	78	-14	-67	-20	N/A
3/31/2019	57	-12	-53	-16	N/A
12/31/2018	41	-2	-40	-10	N/A
9/30/2018	28	0	-26	-4	N/A
6/30/2018	19	1	-23	-7	N/A
3/31/2018	13	1	N/A	-6	N/A
12/31/2017	10	-3	N/A	-5	N/A
12/31/2016	3	-8	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CL ( 7.1% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 6.9% per jaar).

Hoge groei-inkomsten: De omzet van CL ( 7.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CL naar verwachting over 3 jaar hoog zal zijn

Cresco Labs Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Consensus EPS estimates upgraded to US$0.055 loss

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. to Report Q3, 2024 Results on Nov 08, 2024

Cresco Labs Inc. Announces Resignation of Tarik Brooks as Board of Directors

Cresco Labs Inc. Announces CFO Changes

New minor risk - Profitability

No longer forecast to breakeven

Co-Founder & Independent Director recently sold CA$110k worth of stock

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.12 loss in 2Q 2023)

Cresco Labs Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Co-Founder & Independent Director recently sold CA$236k worth of stock

New minor risk - Shareholder dilution

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$124k worth of stock

Co-Founder & Independent Director recently sold CA$364k worth of stock

First quarter 2024 earnings released: US$0.015 loss per share (vs US$0.085 loss in 1Q 2023)

Cresco Labs Inc. (CNSX:CL) acquired Two medical dispensaries in Pennsylvania of Keystone Integrated Care, LLC for $9.8 million.

Consensus EPS estimates upgraded to US$0.055 loss

Cresco Labs Inc. to Report Q1, 2024 Results on May 15, 2024

Cresco Labs Inc., Annual General Meeting, Jun 10, 2024

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.059 loss

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

New minor risk - Profitability

Full year 2023 earnings released: US$0.53 loss per share (vs US$0.71 loss in FY 2022)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Chief Financial Officer exercised options to buy CA$150k worth of stock.

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. to Report Q4, 2023 Results on Mar 13, 2024

Cresco Labs Inc. Promotes Greg Butler to the Position of President

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

New minor risk - Shareholder dilution

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 91%, revenue upgraded

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.033 loss in 3Q 2022)

Cresco Labs Inc. to Report Q3, 2023 Results on Nov 15, 2023

New major risk - Share price stability

Cresco Labs Inc. completed the acquisition of Sole Licensed Arizona Operation of Cresco Labs Inc.

No longer forecast to breakeven

Is Cresco Labs (CSE:CL) Using Too Much Debt?

New minor risk - Shareholder dilution

Consensus EPS estimates fall by 42%

Chief Financial Officer recently bought CA$149k worth of stock

Price target decreased by 8.4% to CA$4.80

Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.046 loss in 2Q 2022)

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs Inc. to Report Q2, 2023 Results on Aug 16, 2023

Insufficient new directors

Consensus EPS estimates fall by 15%

Price target decreased by 36% to CA$3.82

First quarter 2023 earnings released: US$0.092 loss per share (vs US$0.094 loss in 1Q 2022)

Cresco Labs Inc. to Report Q1, 2023 Results on May 24, 2023

Consensus EPS estimates fall by 40%

Insider recently sold CA$157k worth of stock

Consensus EPS estimates fall by 109%

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.22 loss in FY 2021)

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Now 22% undervalued after recent price drop

Co-Founder & Independent Director recently sold CA$1.7m worth of stock

Forecast breakeven date moved forward to 2023

Forecast breakeven date pushed back to 2024

Now 20% undervalued after recent price drop